<DOC>
	<DOCNO>NCT00467285</DOCNO>
	<brief_summary>Subjects diabetes pre-diabetes say increased bone loss compare general population . Pioglitazone thiazolidinedione , Food Drug Administration ( FDA ) approve oral anti-diabetic agent treatment type 2 diabetes . Though many benefit use thiazolidinediones treatment type 2 diabetes , data indicate rosiglitazone therapy result significant decrease total body bone mineral density mouse . Whether true human clear . If animal data extrapolate human , thiazolidinediones may pose significant risk adverse effect bone . This study hypothesize treatment thiazolidinedione pioglitazone may result significant reduction bone mineral density . The aim : 1. evaluate effect pioglitazone skeletal health ; 2. measure bone mineral density ( BMD ) spine hip , well bone turnover marker , different time person take thiazolidinediones others take ; 3. determine change BMD bone turnover marker within different group different time ; 4. compare change .</brief_summary>
	<brief_title>Effect Diabetic Medications Bone Metabolism</brief_title>
	<detailed_description>The prevalence rate diabetes among veteran 16 % general 27 % medical center compare 6.3 % among United States population . Subjects diabetes prediabetes say increased bone loss compare general population . Pioglitazone , thiazolidinedione , Food Drug Administration ( FDA ) approve oral anti-diabetic agent treatment type 2 diabetes . Most pleiotropic effect teh thiazolidinediones beneficial atherosclerosis cancer , addition improve insulin resistance . Data study mice show rosiglitazone pioglitazone therapy result significant decrease total body bone mineral density observe . Whether true human clear . There prospective study date . Subjects diabetes already increase risk femoral fracture . If animal data extrapolate human , thiazolidinedione pioglitazone may result significant risk adverse skeletal effect . This study hypothesize treatment thiazolidinedione pioglitazone may result significant reduction bone mineral density . The aim study include : 1 . To prospectively evaluate effect pioglitazone skeletal health , study 140 subject diabetes receive pioglitazone part diabetes management compare 140 diabetic control ( match age , sex , body mass index ( BMI ) , smoke alcohol history ) , treat pioglitazone . 2 . To measure bone mineral density DXA AP spine hip , well bone turnover markers-procollagen type 1C-terminal propeptide ( P1CP ) , procollagen type 1N-terminal propeptide ( P1NP ) , bone specific alkaline phosphatase , osteocalcin , plasma C-telopeptide ( CTx ) N-telopeptide ( NTx ) baseline , six 12 month follow-up . 3 . To determine change BMD bone turnover marker within group baseline follow-up six 12 month . 4 . To compare change BMD bone turnover marker group baseline follow-up six 12 month . Subjects : Prospectively study 140 subject type 2 diabetes pioglitazone , age , sex match control . Sample Size : The sample size base primary objective comparing level bone turnover marker bone mineral density change diabetes without avandia . Number visit : 140 subject diabetes pioglitazone 140 subject diabetes pioglitazone 1 . Subjects study three visit . 2 . The procedure do include assessment bone mineral density measurement dual X-ray absorptiometry ( DXA ) , measurement bone turnover marker like serum osteocalcin urinary N-telopeptide informed consent . About 15ml ( one tablespoonful ) blood draw visit study . 3 . All baseline measurement repeat 6 month one year . 4 . Statistical analysis data do compare change bone turnover marker bone mineral density two group . Site study : Overton Brooks VAMC Diabetics clinic Primary care clinic . If hypothesis proven correct , subject diabetes require thiazolidinediones bone turnover marker BMD measurement baseline serial follow . Identification subject high risk allow health care provider initiate necessary protective measure protect bone decrease fracture risk . Potential Impact Veterans Health Care : Identification subject high risk allow health care provider initiate necessary preventive measure protect bone decrease risk fracture , avoid use TZDs altogether select patient . Since prevalence diabetes high among veteran , evaluation possible risk skeletal health use pioglitazone highly relevant VA health care .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<criteria>Age 3055 year Gender : men woman Ethnicity : ethnic group 140 subject diabetes pioglitazone ( recently start i.e . le 3 month well initiated pioglitazone treatment ) 140 control subject ( subject diabetes pioglitazone ) include The control subject choose match age , sex , ethnicity comparable smoking alcohol history To avoid confusion factor vitamin D calcium intake , subject give vitamin D calcium supplement ( USDA recommend dos ) Patients unable unwilling yo give inform consent Immobilized bed bound subject Subjects wil know disease associate disorder bone metabolism chronic renal insufficiency , chronic steroid use , primary hyperparathyroidism , untreated subclinical clinical hyperthyroidism Paget 's disease . To identify subject decrease Glomerular filtration rate ( GFR ) even creatinine normal exclude ( propose study site , routine bm include calculated GFR chemistry lab ) Patients medication alter bone metabolism exclude . They glucocorticoids , gonadal hormone ( testosterone men estrogen woman ) . Subjects know history chronic pancreatitis , pancreatectomy malabsorption syndrome avoid confound factor know affect vitamin D metabolism indirectly bone mineral metabolism . Female patient perimenopause menopause : history hypogonadism ( History ovariectomy postmenopausal woman ) avoid bone turn change secondary hypogonadism . Perimenopausal woman identifies screen FSH LH exclude woman elevate FSH exclude avoid perimenopausal effect bone turnover ( woman 35 still screen gonadal hormonal evaluation ) .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Bone Density</keyword>
	<keyword>C-telopeptide</keyword>
	<keyword>Dual-Energy X-Ray Absorptiometry</keyword>
	<keyword>N-telopeptide</keyword>
	<keyword>Osteocalcin</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Thiazolidinediones</keyword>
	<keyword>Type 2 Diabetes Mellitus</keyword>
</DOC>